Denali Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
DNLI$19.85-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating activities | |||
| Net loss | $(145,224) | $(325,991) | $(290,581) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 16,726 | 10,383 | 8,593 |
| Stock-based compensation expense | 108,102 | 99,847 | 85,247 |
| Net amortization of premiums and (discounts) on marketable securities | (43,952) | (1,637) | 8,748 |
| Non-cash adjustment to operating lease expense | (3,719) | (3,351) | (2,984) |
| Other non-cash items | 2 | 63 | — |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other assets | (4,094) | (2,760) | (12,865) |
| Accounts payable | 2,431 | 2,274 | 3,705 |
| Accruals and other current liabilities | 2,648 | 10,918 | 4,732 |
| Contract liabilities | — | (31,313) | (11,925) |
| Related party contract liability | (290,532) | (3,149) | (3,737) |
| Other non-current liabilities | (379) | — | (322) |
| Net cash used in operating activities | (357,991) | (244,716) | (211,389) |
| Investing activities | |||
| Purchases of marketable securities | (1,813,700) | (1,115,040) | (1,422,938) |
| Purchases of property and equipment | (12,939) | (17,833) | (8,500) |
| Maturities and sales of marketable securities | 2,075,947 | 991,486 | 1,409,812 |
| Net cash provided by (used in) investing activities | 249,308 | (141,387) | (21,626) |
| Financing activities | |||
| Proceeds from public offering of common stock, net of issuance costs | — | 296,215 | — |
| Proceeds from exercise of awards under equity incentive plans | 17,820 | 14,455 | 19,348 |
| Net cash provided by financing activities | 17,820 | 310,670 | 19,348 |
| Net decrease in cash, cash equivalents and restricted cash | (90,863) | (75,433) | (213,667) |
| Cash, cash equivalents and restricted cash at beginning of year | 219,544 | 294,977 | 508,644 |
| Cash, cash equivalents and restricted cash at end of year | $128,681 | $219,544 | $294,977 |
| Supplemental disclosures of cash flow information | |||
| Cash paid during the year for income taxes | $3 | $47 | $210 |
| Issuance costs incurred but not yet paid | $— | $224 | $— |
| Property and equipment purchases accrued but not yet paid | $553 | $1,464 | $593 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.